- ~300%Testing volume growth in the first month
- 2,000%+Peak volume growth above the original baseline
The challenge
The laboratory had an established provider network and strong demand for hereditary cancer testing. The science and the demand were there. The bottleneck was turning fragmented provider workflows and inconsistent patient identification into a scalable, repeatable path from risk assessment to completed test.
- Eligible patients were not consistently identified for genetic testing.
- Identification depended heavily on individual provider knowledge and workflow.
- Clinical encounters left little time for patient education.
- Several steps separated patient identification from a completed test.
- Growth relied on repeated sales-representative visits and could not scale without adding sales resources.
How OptraHEALTH helped
OptraHEALTH embedded patient identification, provider support and test acquisition directly into the workflow, as one digital pathway: identify, educate, guide, acquire.
Intelligent risk identification
A digital risk assessment flagged patients who may meet clinical criteria for hereditary cancer testing, based on personal and family history.
Provider decision support
Providers received structured information to confirm appropriate testing candidates and guide the next step.
Patient education and test acquisition
Patients received accessible education, financial guidance and support, creating a direct path from qualification to completed test.
Clinical decisions stay with the care team
The platform reduces the burden of identification and education on busy clinicians. It does not replace providers or clinical judgment.
Results
Testing volume grew roughly 300% in the first month after implementation and peaked at more than 2,000% above the original baseline as adoption spread across the provider network. Volume scaled without sales headcount growing at the same rate, improving the return on commercial investment.
Instead of depending on individual provider behavior or repeated rep visits, the laboratory now identifies eligible patients consistently, supports providers at the point of care, and moves patients through acquisition at scale.
Best fit
- Hereditary cancer testing programs
- Pharmacogenomics and precision medicine
- Rare disease and specialty diagnostics
- Provider network expansion
- Commercial scaling without proportional headcount growth